The ASCO roundup: ArQule drug flunks a mid-stage test

Plenty of more early-stage and mid-stage study results came to light at ASCO over the past day. Here are some of the highlights: ArQule said that its lung cancer drug flunked a mid-stage study, but it flagged some positive results for a subset of patients taking the therapy. About two thirds of the patients taking a combination of ARQ-197 and Tarceva demonstrated an improvement in survival rates, but that wasn't enough to give it a significant statistical edge over Tarceva alone. Patients...